 Receptor, IGF Type 1
"Receptor, IGF Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
| Descriptor ID |
D017526
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.185 D12.776.543.750.630.468 D12.776.543.750.750.400.780.400
|
| Concept/Terms |
Receptor, IGF Type 1- Receptor, IGF Type 1
- Receptors, IGF-1
- IGF-1 Receptors
- Receptors, IGF 1
- IGF-1 Receptor
- IGF 1 Receptor
- Receptor, IGF-1
- Receptors, Insulin-Like-Growth Factor I
- IGF-I Receptor
- IGF I Receptor
- Receptor, Insulin-Like Growth Factor Type 1
- Receptor, IGF-I
- Receptor, IGF I
- Receptor, Insulin-Like Growth Factor I
- Insulin-Like-Growth Factor I Receptor
- Insulin Like Growth Factor I Receptor
- IGF Type 1 Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, IGF Type 1".
Below are MeSH descriptors whose meaning is more specific than "Receptor, IGF Type 1".
This graph shows the total number of publications written about "Receptor, IGF Type 1" by people in this website by year, and whether "Receptor, IGF Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 2006 | 4 | 4 | 8 | | 2007 | 1 | 1 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 6 | 5 | 11 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 3 | 1 | 4 | | 2016 | 0 | 2 | 2 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, IGF Type 1" by people in Profiles.
-
Nandi P, Jang CE, Biggar K, Halari CD, Jansson T, Gupta MB. Mechanistic Target of Rapamycin Complex 1 Signaling Links Hypoxia to Increased IGFBP-1 Phosphorylation in Primary Human Decidualized Endometrial Stromal Cells. Biomolecules. 2021 09 18; 11(9).
-
Oherle K, Acker E, Bonfield M, Wang T, Gray J, Lang I, Bridges J, Lewkowich I, Xu Y, Ahlfeld S, Zacharias W, Alenghat T, Deshmukh H. Insulin-like Growth Factor 1 Supports a Pulmonary Niche that Promotes Type 3 Innate Lymphoid Cell Development in Newborn Lungs. Immunity. 2020 02 18; 52(2):275-294.e9.
-
Xu F, Takahashi H, Tanaka Y, Ichinose S, Niwa S, Wicklund MP, Hirokawa N. KIF1B? mutations detected in hereditary neuropathy impair IGF1R transport and axon growth. J Cell Biol. 2018 10 01; 217(10):3480-3496.
-
Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res. 2018 10 15; 24(20):5165-5177.
-
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 05 04; 376(18):1748-1761.
-
Sun RC, Choi PM, Diaz-Miron JL, Sommovilla J, Guo J, Erwin CR, Warner BW. Epithelial IGF1R is dispensable for IGF2 mediated enhanced intestinal adaptation in retinoblastoma-deficient mice. J Pediatr Surg. 2017 Jun; 52(6):1026-1030.
-
Cui M, Wang Y, Cavaleri J, Kelson T, Teng Y, Han M. Starvation-Induced Stress Response Is Critically Impacted by Ceramide Levels in Caenorhabditis elegans. Genetics. 2017 02; 205(2):775-785.
-
Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget. 2016 Jan 19; 7(3):2921-35.
-
Damerill I, Biggar KK, Abu Shehab M, Li SS, Jansson T, Gupta MB. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition. Mol Endocrinol. 2016 Feb; 30(2):201-16.
-
Sanderson MP, Apgar J, Garin-Chesa P, Hofmann MH, Kessler D, Quant J, Savchenko A, Schaaf O, Treu M, Tye H, Zahn SK, Zoephel A, Haaksma E, Adolf GR, Kraut N. BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. Mol Cancer Ther. 2015 Dec; 14(12):2762-72.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|